Riddha Das

I am a biomedical researcher working at the intersection of nanomedicine, immunoengineering, and biomaterials. My research focuses on developing next-generation therapeutic platforms that can activate, engineer, and reprogram immune cells for cancer immunotherapy, autoimmune diseases, and women’s health.

I earned my Ph.D. in Chemistry at UMass Amherst with Prof. Vincent Rotello, followed by postdoctoral training at Tufts University with Prof. Sameer Sonkusale in biomaterials and wearable technologies. Most recently, as an NIH T32 Research Fellow at Massachusetts General Hospital and Harvard Medical School with Prof. Ralph Weissleder, I developed lipid nanoparticle-mRNA-based immune-remodeling strategies for cancer immunotherapy.

My research program seeks to uncover immune-control pathways and transform these insights into programmable therapeutic platforms. My long-term goal is to develop clinically translatable therapeutic approaches that benefit human health.